Chronic myeloid leukemia: Current application of cytogenetics and molecular testing for diagnosis and treatment

Ayalew Tefferi, Gordon W. Dewald, Mark R Litzow, Jorge Cortes, Michael J. Mauro, Moshe Talpaz, Hagop M. Kantarjian

Research output: Contribution to journalArticle

50 Scopus citations


Chronic myeloid leukemia provides an illustrative disease model for both molecular pathogenesis of cancer and rational drug therapy. Chronic myeloid leukemia is a clonal stem cell disease caused by an acquired somatic mutation that fuses, through chromosomal translocation, the abl and bcr genes on chromosomes 9 and 22, respectively. The bcr/abl gene product is an oncogenic protein that localizes to the cytoskeleton and displays an up-regulated tyrosine kinase activity that leads to the recruitment of downstream effectors of cell proliferation and cell survival and consequently cell transformation. Such molecular information on pathogenesis has facilitated accurate diagnosis, the development of pathogenesis-targeted drug therapy, and most recently the application of molecular techniques for monitoring minimal residual disease after successful therapy. These issues are discussed within the context of clinical practice.

Original languageEnglish (US)
Pages (from-to)390-402
Number of pages13
JournalMayo Clinic Proceedings
Issue number3
StatePublished - 2005


ASJC Scopus subject areas

  • Medicine(all)

Cite this